Kathryn Haviland's most recent trade in Fulcrum Therapeutics Inc was a trade of 36,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics Inc | Kathryn Haviland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 36,000 | 36,000 | - | - | Stock Option (right to buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 87.34 per share. | 01 Apr 2025 | 1,200 | 166,029 (0%) | 0% | 87.3 | 104,808 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 85.47 per share. | 01 Apr 2025 | 600 | 167,827 (0%) | 0% | 85.5 | 51,282 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 86.14 per share. | 01 Apr 2025 | 598 | 167,229 (0%) | 0% | 86.1 | 51,512 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 88.59 per share. | 01 Apr 2025 | 100 | 165,929 (0%) | 0% | 88.6 | 8,859 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 88.80 per share. | 05 Mar 2025 | 16,151 | 168,427 (0%) | 0% | 88.8 | 1,434,209 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 70,400 | 70,400 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 35,200 | 184,578 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 110.24 per share. | 21 Jan 2025 | 1,446 | 149,378 (0%) | 0% | 110.2 | 159,407 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 96.74 per share. | 29 Nov 2024 | 1,746 | 151,031 (0%) | 0% | 96.7 | 168,908 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 95.40 per share. | 29 Nov 2024 | 400 | 152,777 (0%) | 0% | 95.4 | 38,160 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 97.76 per share. | 29 Nov 2024 | 207 | 150,824 (0%) | 0% | 97.8 | 20,236 | Common Stock |
| Fulcrum Therapeutics Inc | Kathryn Haviland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 90.69 per share. | 07 Mar 2024 | 12,464 | 153,177 (0%) | 0% | 90.7 | 1,130,360 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 40,000 | 165,641 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 45.72 per share. | 06 Mar 2023 | 6,428 | 125,853 (0%) | 0% | 45.7 | 293,888 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 44.65 per share. | 06 Mar 2023 | 212 | 125,641 (0%) | 0% | 44.7 | 9,466 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 40,000 | 132,281 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 43.98 per share. | 03 Nov 2022 | 1,100 | 92,281 (0%) | 0% | 44.0 | 48,378 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 60.27 per share. | 03 Mar 2022 | 1,719 | 92,229 (0%) | 0% | 60.3 | 103,604 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 56.18 per share. | 03 Mar 2022 | 1,048 | 91,181 (0%) | 0% | 56.2 | 58,877 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 40,000 | 93,948 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 13 Dec 2021 | 1,000 | 54,948 (0%) | 0% | 36.1 | 36,050 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 1,000 | 591 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 97.60 per share. | 13 Dec 2021 | 411 | 54,042 (0%) | 0% | 97.6 | 40,114 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 99.65 per share. | 13 Dec 2021 | 285 | 54,663 (0%) | 0% | 99.6 | 28,400 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 98.50 per share. | 13 Dec 2021 | 210 | 54,453 (0%) | 0% | 98.5 | 20,685 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 96.78 per share. | 13 Dec 2021 | 94 | 53,948 (0%) | 0% | 96.8 | 9,097 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 1,000 | 1,591 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 13 Sep 2021 | 1,000 | 54,948 (0%) | 0% | 36.1 | 36,050 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 99.25 per share. | 13 Sep 2021 | 417 | 53,984 (0%) | 0% | 99.2 | 41,387 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 101.11 per share. | 13 Sep 2021 | 286 | 54,662 (0%) | 0% | 101.1 | 28,917 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 99.98 per share. | 13 Sep 2021 | 261 | 54,401 (0%) | 0% | 100.0 | 26,095 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 98.39 per share. | 13 Sep 2021 | 28 | 53,956 (0%) | 0% | 98.4 | 2,755 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 97.62 per share. | 13 Sep 2021 | 8 | 53,948 (0%) | 0% | 97.6 | 781 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 28 Jun 2021 | 1,000 | 54,948 (0%) | 0% | 36.1 | 36,050 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 1,000 | 2,591 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 89.91 per share. | 28 Jun 2021 | 622 | 53,972 (0%) | 0% | 89.9 | 55,924 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 90.88 per share. | 28 Jun 2021 | 354 | 54,594 (0%) | 0% | 90.9 | 32,172 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 89.29 per share. | 28 Jun 2021 | 24 | 53,948 (0%) | 0% | 89.3 | 2,143 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 1,000 | 3,591 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 15 Mar 2021 | 1,000 | 54,948 (0%) | 0% | 36.1 | 36,050 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 105.44 per share. | 15 Mar 2021 | 426 | 54,270 (0%) | 0% | 105.4 | 44,917 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 104.65 per share. | 15 Mar 2021 | 322 | 53,948 (0%) | 0% | 104.6 | 33,697 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 107.42 per share. | 15 Mar 2021 | 138 | 54,804 (0%) | 0% | 107.4 | 14,824 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 106.62 per share. | 15 Mar 2021 | 108 | 54,696 (0%) | 0% | 106.6 | 11,515 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 108.17 per share. | 15 Mar 2021 | 6 | 54,942 (0%) | 0% | 108.2 | 649 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 86.61 per share. | 04 Mar 2021 | 1,828 | 53,948 (0%) | 0% | 86.6 | 158,323 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 89.09 per share. | 04 Mar 2021 | 124 | 55,776 (0%) | 0% | 89.1 | 11,047 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 26,125 | 26,125 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 13,062 | 55,900 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 409 | 4,591 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 100.27 per share. | 16 Nov 2020 | 409 | 42,838 (0%) | 0% | 100.3 | 41,010 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 16 Nov 2020 | 409 | 43,247 (0%) | 0% | 36.0 | 14,744 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 16 Oct 2020 | 13,334 | 56,172 (0%) | 0% | 36.1 | 480,691 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 13,334 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 100.55 per share. | 16 Oct 2020 | 7,200 | 42,838 (0%) | 0% | 100.6 | 723,960 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 101.56 per share. | 16 Oct 2020 | 3,125 | 50,038 (0%) | 0% | 101.6 | 317,375 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 102.53 per share. | 16 Oct 2020 | 3,009 | 53,163 (0%) | 0% | 102.5 | 308,513 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.28 per share. | 22 Sep 2020 | 3,143 | 45,981 (0%) | 0% | 16.3 | 51,168 | Common Stock |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Sep 2020 | 3,143 | 2 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Kathryn Haviland | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 85.49 per share. | 22 Sep 2020 | 3,143 | 42,838 (0%) | 0% | 85.5 | 268,695 | Common Stock |